ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million.

The company is also conducting a Phase 1b clinical trial in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD) and a Phase 1b clinical trial in patients with progressing open-angle glaucoma.

Onl Therapeutics Closes 2Nd Tranche Of $46.9 Million Series B Financing Upon Achieving Onl1204 Development Milestones

Description

Company Information

Funding Insights

Onl Therapeutics Closes 2Nd Tranche Of $46.9 Million Series B Financing Upon Achieving Onl1204 Development Milestones

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information